Moricizine

Jump to: navigation, search
Moricizine
Moricizine.png
Clinical data
Pregnancy
category
  • B (U.S.)
Pharmacokinetic data
Bioavailability38%
Protein binding95%
Elimination half-life3-4 hours (healthy volunteers), 6-13 hours (cardiac disease)
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H25N3O4S
Molar mass427.518 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]



For patient information, click here

Overview

Moricizine is a phenothiazine derivative with Vaughan Williams class IC antiarrhythmic properties. It undergoes extensive first-pass metabolism, has a bioavailability of 34-38 percent, and is 95 percent bound to plasma proteins. Moricizine is extensively metabolized and may have pharmacologically active metabolites. A recent clinical study has shown that moricizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations. Compared with disopyramide and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, couplets, and nonsustained ventricular tachycardia. Further studies are needed comparing moricizine with other class 1 agents in the treatment of life-threatening arrhythmias; available data suggest that moricizine is comparable with these agents in the treatment of ventricular tachycardias and fibrillation. Moricizine appears to have a low incidence of serious adverse effects compared with other antiarrhythmics. This combination of apparently similar efficacy with a decreased incidence of adverse effects makes moricizine a worthwhile addition to currently available antiarrhythmic agents.

External links


de:Moricizin



Linked-in.jpg